Insights

  • Date

  • Content Type

  • Reset

Blog

Gene editing drugs – clinical potential and important regulatory considerations

6.10.19

By Maria Schacker and Diane Seimetz

Your gene editing drugs are at the forefront of science – but you are no longer the...

Read More

Blog

Platform technologies for vaccines – why is there still no regulatory guidance available?

3.09.19

By Michael Pfleiderer

The recent widespread, long-lasting and recurrent outbreaks of Ebolavirus, Chikungunyavirus, Denguevirus, Zikavirus once more prove the need...

Read More

Blog

What’s the risk? – How to approach the risk management process of a medical device

28.08.19

By Liron Sarid-Krebs

Risk management is an essential part of any pharmaceutical development. This is even more true in the...

Read More

Blog

Four Tips for Successful MAA Preparation based on Real-World Experience

23.07.19

By Brenda Rascon

A Marketing Authorization Application (MAA), New Drug Application (NDA) or Biologics License Application (BLA) is the grand...

Read More

Blog

How Biologicals Have Changed the Paradigm of How We Treat Diseases Today and in the Future

21.06.19

By Diane Seimetz

Biologics have been gaining importance rapidly over the past 30 years. Over this time, new developments revolutionized...

Read More

Blog

Artificial Intelligence – A Revolution in Biopharmaceutical Development

11.06.19

By Michael Firgens

As Artificial Intelligence (AI) is becoming more and more present throughout industries, first applications of AI have...

Read More

We are now Cencora PharmaLex 

PharmaLex is now part of Cencora, a leading global healthcare company with a foundation in pharmaceutical distribution. In 2024 and beyond PharmaLex and all the companies in PharmaLex family will begin a journey to becoming Cencora as well. Cencora brings the companies and services together under one new name. The name will change, but the level of attention and service you receive remains the same.  

Know more